New pill shows promise for rare lung cancer mutations
NCT ID NCT06010329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing an oral drug called sutetinib maleate in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors and control the disease. About 66 adults will take the drug and be monitored for response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sutetinib maleate (a targeted cancer drug taken orally)
What this could lead to
If successful, this could provide a new treatment option for people with non-small cell lung cancer that has uncommon EGFR mutations, potentially shrinking tumors and delaying progression.
What could go wrong
This is an early-phase (Phase 2) trial with only 66 participants, so results may not apply to everyone. The drug may cause side effects and may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mission Cancer + Blood - Mission Cancer Foundation
RECRUITINGDes Moines, Iowa, 50309, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Northwell Health
ACTIVE_NOT_RECRUITINGNew Hyde Park, New York, 11042, United States
-
Norton Cancer Institute - Downtown
WITHDRAWNLouisville, Kentucky, 40202, United States
-
Oncology Physicians Network Healthcare
WITHDRAWNGlendale, California, 91203, United States
-
Perlmutter Cancer Center - 34th Street
RECRUITINGNew York, New York, 10016, United States
-
University Cancer & Blood Center (UCBC) - Athens
RECRUITINGAthens, Georgia, 30607, United States
-
University of California San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States